A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
LEO Pharma
ClinicalTrials.gov Identifier:
NCT01607853
First received: May 23, 2012
Last updated: January 7, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to evaluate the anti-psoriatic effect of Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes), Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes) compared with Daivobet® gel and Daivobet® gel vehicle applied for 24 hours (+/- 2 hours), using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.


Condition Intervention Phase
Psoriasis Vulgaris
Drug: Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)
Drug: Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)
Drug: Daivobet® gel applied for 24 hours (+/- 2 hours)
Drug: Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Investigator)
Official Title: A Phase IIa Exploratory Study Evaluating the Anti-psoriatic Effect of Daivobet® Gel Applied Then Removed After 10 Minutes, Daivobet® Gel Applied Then Removed After 20 Minutes, Daivobet® Gel Applied for 24 Hours and Daivobet® Gel Vehicle Applied for 24 Hours

Resource links provided by NLM:


Further study details as provided by LEO Pharma:

Primary Outcome Measures:
  • Change in Total Clinical Score From Baseline to Day 22 [ Time Frame: baseline to day 22 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of a psoriatic lesion. Maximum score is 9 (most severe); minimum score is 0 (least severe). The single items erythema, scaling, and infiltration (maximum score 3 each) are summed to obtain the Total Clincal Score


Secondary Outcome Measures:
  • Change in Total Clinical Score at Day 4 Compared to Baseline [ Time Frame: Baseline to day 4 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of a psoriatic lesion. Maximum score is 9 (most severe); minimum score is 0 (least severe). The single items erythema, scaling, and infiltration (maximum score 3 each) are summed to obtain the Total Clinical Score.

  • Change in Total Clinical Score at Day 8 Compared to Baseline [ Time Frame: Baseline to day 8 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of a psoriatic lesion. Maximum score is 9 (most severe); minimum score is 0 (least severe). The single items erythema, scaling, and infiltration (maximum score 3 each) are summed to obtain the Total Clinical Score.

  • Change in Total Clinical Score at Day 11 Compared to Baseline [ Time Frame: Baseline to day 11 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of a psoriatic lesion. Maximum score is 9 (most severe); minimum score is 0 (least severe). The single items erythema, scaling, and infiltration (maximum score 3 each) are summed to obtain the Total Clinical Score.

  • Change in Total Clinical Score at Day 15 Compared to Baseline [ Time Frame: Baseline to day 15 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of a psoriatic lesion. Maximum score is 9 (most severe); minimum score is 0 (least severe). The single items erythema, scaling, and infiltration (maximum score 3 each) are summed to obtain the Total Clinial Score.

  • Change in Total Clinical Score at Day 18 Compared to Baseline [ Time Frame: Baseline to day 18 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of a psoriatic lesion. Maximum score is 9 (most severe); minimum score is 0 (least severe). The single items erythema, scaling, and infiltration (maximum score 3 each) are summed to obtain the Total Clinical Score.

  • Change From Baseline in Erythema at Day 4. [ Time Frame: Baseline to day 4 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of erythema. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Erythema at Day 8. [ Time Frame: Baseline to day 8 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of erythema. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Erythema at Day 11 [ Time Frame: Baseline to day 11 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of erythema. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Erythema at Day 15 [ Time Frame: Baseline to day 15 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of erythema. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Erythema at Day 18 [ Time Frame: Baseline to day 18 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of erythema. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Erythema at Day 22 [ Time Frame: Baseline to day 22 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of erythema. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Infiltration at Day 4 [ Time Frame: Baseline to day 4 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of infiltration. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Infiltration at Day 8 [ Time Frame: Baseline to day 8 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of infiltration. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Infiltration at Day 11 [ Time Frame: Baseline to day 11 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of infiltration. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Infiltration at Day 15 [ Time Frame: Baseline to day 15 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of infiltration. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Infiltration at Day 18 [ Time Frame: Baseline to day 18 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of infiltration. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Infiltration at Day 22 [ Time Frame: Baseline to day 22 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of infiltration. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Scaling at Day 4 [ Time Frame: Baseline to day 4 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of scaling. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Scaling at Day 8 [ Time Frame: Baseline to day 8 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of scaling. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Scaling at Day 11 [ Time Frame: Baseline to day 11 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of scaling. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Scaling at Day 15 [ Time Frame: Baseline to day 15 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of scaling. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Scaling at Day 18 [ Time Frame: Baseline to day 18 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of scaling. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change From Baseline in Scaling at Day 22 [ Time Frame: Baseline to day 22 ] [ Designated as safety issue: No ]
    Investigator's rating of the clinical appearance of scaling. Maximum score is 3 (most severe); minimum score is 0 (absent).

  • Change in Lesion Thickness Measured by Ultrasound From Baseline to Day 22. [ Time Frame: Baseline to day 22 ] [ Designated as safety issue: No ]
  • Change in Skin Thickness - Echo-poor Band - Measured by Ultrasound From Baseline to Day 22 [ Time Frame: Baseline to day 22 ] [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: June 2012
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Daivobet® gel Drug: Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)
Once daily application, 3 weeks
Drug: Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)
Once daily application, 3 weeks
Drug: Daivobet® gel applied for 24 hours (+/- 2 hours)
Once daily application, 3 weeks
Drug: Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)
Once daily application, 3 weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Following verbal and written information about the trial, the subject has to provide signed and dated informed consent before any study related activities are carried out.
  2. Age 18 years or above.
  3. Either sex.
  4. All skin types.
  5. Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs and/or trunk. The lesions must have a total size suitable for application of 4 different products.
  6. Subjects with, in the opinion of the investigator, stable psoriasis based on Total Plaque Score evaluated at screening visit and at visit 2 (baseline).
  7. Subjects with psoriasis lesions (plaques) assessed by a Total Clinical Score (sum of scores of erythema, scaling and infiltration) of 4 to 9 inclusive, but each individual item ≥ 1.
  8. Subjects willing and able to follow all the study procedures and complete the whole study.
  9. Subjects affiliated to a social security system.
  10. Female subjects of childbearing potential using a reliable method of contraception for at least 1 month before the study start and during the course of the study (e.g., oral contraceptive pill, intrauterine device, contraceptive patches, implantable contraception, condoms) or females of non-childbearing potential (i.e. postmenopausal (absence of menstrual bleeding for 2 years), hysterectomy, bilateral ovariectomy or tubal section/ligation).
  11. Female with a negative urine pregnancy test (at screening visit).

Exclusion Criteria:

  1. Females who are pregnant, of child-bearing potential and who wish to become pregnant during the study, or who are breast feeding.
  2. Systemic treatment with biological therapies (marketed or not marketed) with a possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2 months (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 half-lives (which-ever is longer) for experimental biological products prior to randomisation and during the study.
  3. Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within the 4- week period prior to randomisation and during the study.
  4. Use of phototherapy within the following time periods prior to randomisation and during the study:

    • PUVA or Grenz ray therapy (4 weeks),
    • UVB (2 weeks).
  5. Subjects using one of the following topical drugs within 4 weeks prior to randomisation and during the study:

    - Potent or very potent (WHO group III-IV) corticosteroids.

  6. Subjects using one of the following topical drugs for the treatment of psoriasis within 2 weeks prior to randomisation and during the study:

    • WHO group I-II corticosteroids (except if used for treatment of scalp and/or facial psoriasis),
    • Topical retinoids,
    • Vitamin D analogues,
    • Topical immunomodulators (e.g. calcineurin inhibitors),
    • Anthracen derivatives,
    • Tar,
    • Salicylic acid.
  7. Subjects using emollients on the target plaques within one week before randomisation and during the study.
  8. Initiation of, or expected changes in concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) within 2 weeks prior to randomisation and during the study.
  9. Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.
  10. Subjects with known/suspected disorders of calcium metabolism associated with hypercalcemia within the last 10 years, based on medical history.
  11. Subjects with any of the following conditions present on the test area: viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections and atrophic skin.
  12. Subjects with skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, icthyosis, acne rosacea, ulcers and wounds within the plaque test areas.
  13. History of any severe disease or serious current condition (based on subject interview and/or results of screening physical examination) which, in the opinion of the investigator, would put the subject at risk by participating in the study or would interfere significantly with the evaluation of study results or the study course (e.g. cancer, severe cardiopathy, severe renal insufficiency, severe hepatic insufficiency).
  14. Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within the 4 week period prior to randomisation or longer, if the class of the substance requires a longer washout as defined above (e.g., biological treatments).
  15. Subjects with current participation in any other interventional clinical trial, based on interview of the subject.
  16. Subjects with known or suspected hypersensitivity to component(s) of the investigational products.
  17. Subjects with any concomitant medical or dermatological disorder(s) which might preclude accurate evaluation of the psoriasis.
  18. Subjects foreseeing an intensive solar exposure during the study (UV radiation, etc.) or having been exposed within two weeks preceding the screening visit.
  19. Subjects impossible to contact in case of emergency.
  20. Subjects who are known or, in the opinion of the investigator, are unlikely to comply with the Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state).
  21. Subjects who are in an exclusion period in the National Biomedical Research Register of the French Ministry of Health at randomisation.
  22. Subjects under guardianship, hospitalized in a public or private institution, for a reason other than the research or subject deprived of freedom.
  23. Subjects previously randomised in this trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01607853

Locations
France
Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD)
Nice, France, 06202
Sponsors and Collaborators
LEO Pharma
Investigators
Principal Investigator: Catherine Queille-Roussel, MD Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Hôpital l'Archet 2, 151 route Saint-Antoine de Ginestière 06202 Nice Cedex 3, France
  More Information

No publications provided

Responsible Party: LEO Pharma
ClinicalTrials.gov Identifier: NCT01607853     History of Changes
Other Study ID Numbers: LP0076-57, 2012-001507-21
Study First Received: May 23, 2012
Results First Received: November 4, 2013
Last Updated: January 7, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases

ClinicalTrials.gov processed this record on September 11, 2014